Distinguished in Thymic Epithelial Tumor

Dr. Leena V. Gandhi

Hematology Oncology | Oncology

450 Brookline Ave,

Boston, MA

Clinical Trials:Currently Recruiting for 3 Trials

Distinguished in Thymic Epithelial Tumor

450 Brookline Ave,

Boston, MA

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Leena Gandhi is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Gandhi is rated as a Distinguished provider by MediFind in the treatment of Thymic Epithelial Tumor. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Thymic Epithelial Tumor.

Her clinical research consists of co-authoring 67 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology Oncology

Oncology

Licenses

Internal Medicine in MA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Anthem

Blue Cross Blue Shield

Humana

HMO
INDEMNITY
POS
PPO

Locations

450 Brookline Ave, Boston, MA 02215

Call: 617-632-6049

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors

Enrollment Status: Recruiting

Publish Date: September 12, 2025

Intervention Type: Drug

Study Drug: SGN-B6A

Study Phase: Phase 1

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Enrollment Status: Recruiting

Publish Date: May 15, 2025

Intervention Type: Drug

Study Drugs: CPI-0209, Irinotecan

Study Phase: Phase 1/Phase 2

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Enrollment Status: Recruiting

Publish Date: July 03, 2024

Intervention Type: Other, Drug

Study Drug: Crizotinib

Study Phase: Phase 3

A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies

Enrollment Status: Completed

Publish Date: October 10, 2025

Intervention Type: Drug

Study Phase: Phase 2/Phase 3

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Enrollment Status: Active_not_recruiting

Publish Date: July 04, 2025

Intervention Type: Drug

Study Drugs: Itacitinib, Osimertinib

Study Phase: Phase 1/Phase 2

A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

Enrollment Status: Terminated

Publish Date: April 03, 2024

Intervention Type: Drug

Study Drug: Poziotinib

Study Phase: Phase 2

A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer

Enrollment Status: Terminated

Publish Date: October 17, 2023

Intervention Type: Drug

Study Phase: Phase 2

A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: October 16, 2023

Intervention Type: Drug

Study Phase: Phase 1

Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Alone and in Combination With Chemotherapy.

Enrollment Status: Terminated

Publish Date: July 24, 2023

Intervention Type: Drug

Study Drugs: Pembrolizumab, Carboplatin, Nab-paclitaxel, Pemetrexed

Study Phase: Phase 2

Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma

Enrollment Status: Completed

Publish Date: July 05, 2023

Intervention Type: Drug

Study Drug: Durvalumab

Study Phase: Phase 2

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Enrollment Status: Terminated

Publish Date: March 17, 2023

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Phase I/II Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy

Enrollment Status: Unknown

Publish Date: February 07, 2022

Intervention Type: Drug

Study Drugs: Olaparib, Temozolomide

Study Phase: Phase 1/Phase 2

A Phase II Study of Pembrolizumab and Dynamic PD-L1 Expression in Extensive Stage Small Cell Lung Cancer (SCLC)

Enrollment Status: Terminated

Publish Date: November 16, 2021

Intervention Type: Drug, Radiation, Biological

Study Phase: Phase 2

Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer

Enrollment Status: Completed

Publish Date: October 06, 2021

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase II Study of Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC)

Enrollment Status: Completed

Publish Date: April 23, 2019

Intervention Type: Drug

Study Phase: Phase 2

A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 With Pembrolizumab in Adults With Previously-Treated Malignant Pleural Mesothelioma

Enrollment Status: Terminated

Publish Date: April 04, 2019

Intervention Type: Biological

Study Phase: Phase 2

Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Enrollment Status: Completed

Publish Date: April 10, 2018

Intervention Type: Drug

Study Phase: Phase 2

View 16 Less Clinical Trials

66 Total Publications

Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 31, 2025

View All 66 Publications

Similar Doctors

Distinguished in Thymic Epithelial Tumor

Dr. Michael S. Rabin

Oncology | Hematology

Distinguished in Thymic Epithelial Tumor

Dr. Michael S. Rabin

Oncology | Hematology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave,

Boston, MA

(0.1 miles away)

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Michael Rabin is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Rabin is rated as an Elite provider by MediFind in the treatment of Thymic Epithelial Tumor. His top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Rabin is currently accepting new patients.

Distinguished in Thymic Epithelial Tumor

Dr. Daniel B. Costa

Hematology Oncology | Hematology

Distinguished in Thymic Epithelial Tumor

Dr. Daniel B. Costa

Hematology Oncology | Hematology

Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc

330 Brookline Ave,

Boston, MA

(0.2 miles away)

617-754-8612

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Daniel Costa is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Costa is rated as an Elite provider by MediFind in the treatment of Thymic Epithelial Tumor. His top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Costa is currently accepting new patients.

Advanced in Thymic Epithelial Tumor

Dr. Murat A. Anamur

Oncology | Hematology Oncology | Hematology

Advanced in Thymic Epithelial Tumor

Dr. Murat A. Anamur

Oncology | Hematology Oncology | Hematology

Associated Physicians Of Harvard Medical Faculty Physicians At Beth Is

1 Wallace Bashaw Way, 2001 Anna Jacques Cancer C,

Newburyport, MA

(34.5 miles away)

978-463-1374

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Murat Anamur is an Oncologist and a Hematologist Oncology provider in Newburyport, Massachusetts. Dr. Anamur is rated as a Distinguished provider by MediFind in the treatment of Thymic Epithelial Tumor. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Anal Cancer. Dr. Anamur is currently accepting new patients.

VIEW MORE THYMIC EPITHELIAL TUMOR DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gandhi's expertise for a condition

ConditionClose